Upcoming Research

An open label randomised-controlled trial to evaluate the benefit-risk of 1-month rifapentine and isoniazid compared to standard of care to prevent tuberculosis and reduce morbidity in people with diabetes in South Africa

Principal Investigator — Dr. Charles Y. Yu

Status — To Start (June 2026)

 

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major AdverseCardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Even

Principal Investigator — Dr. Andre Luis R. Agoncillo

Status — To Start (July 2026)

 

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Verekitug in Adolescent and Adult Participants with Severe Asthma

Principal Investigator — Dr. Charles Y. Yu

Status — Start-up Phase

 

A benefit-risk trial of 1-month rifapentine and isoniazid to prevent tuberculosis and reduce morbidity in people with non-communicable multimorbidity

Next
Next

Ongoing Research